6505--Atropine Sulfate Injections

The Department of Veterans Affairs National Acquisition Center is soliciting competitive bids for Atropine Sulfate Syringes (0.1MG/ML, 10ML) under solicitation number 36E79725R0049. This procurement is specifically limited to U.S.-manufactured products and seeks a single award for a five-year contract consisting of a base year plus four option years through the VA Pharmaceutical Prime Vendor Program. Offerors must provide a unique 11-digit National Drug Code number, maintain FDA current Good Manufacturing Practices certification, and submit a Letter of Commitment from the manufacturer if they are not the manufacturer themselves. Pricing submissions must include costs for all five contract years with prices not exceeding two decimal places and must incorporate a 0.5% Cost Recovery Fee. The solicitation was issued on August 27, 2025, with proposals due by September 29, 2025 at 2:30 PM Central Time.

This procurement does not utilize any set-aside designations and is open to full and open competition among qualified U.S. manufacturers. The contract involves an estimated annual usage of 97,550 syringes, with the total contract value to be determined by multiplying the estimated quantities by the unit prices offered for each contract year. McKesson Corporation serves as the current VA Pharmaceutical Prime Vendor and will handle distribution of the contracted products. The five-year contract structure provides the VA with flexibility through option years while ensuring a stable supply chain for this critical medical supply. Competition is restricted to domestic production, requiring offerors to certify that their products are manufactured in the United States as part of the procurement's Buy American requirements.